AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript February 20, 2024 AbCellera Biologics Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.14. AbCellera Biologics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]